Caregen (CEO Yongji Jeong) announced on the 19th that its oral GLP-1R/IGF-1R dual-action peptide 'Korglutide' has completed official registration with the Mexican health authorities COFEPRIS.
This registration was conducted jointly with IFA Celtics, Mexico's largest pharmaceutical distributor, and the two companies signed an exclusive distribution agreement worth a total of $42 million. Coglutide is registered locally under the trademark "Trimtide®" and will be available starting in March, primarily through Doctors Market and major pharmacy chains.
Mexico, where more than seven in 10 adults are overweight according to OECD standards, has a diabetes prevalence rate of 16.9%, nearly double the OECD average. This creates a high demand for obesity and metabolic disease treatments. Coglutide simultaneously supports weight and body fat reduction and muscle mass improvement, and is considered a more convenient and accessible oral treatment than existing injectable GLP-1 inhibitors.
Caregen plans to use this Mexican registration as a springboard to secure a foothold in the Central and South American market and accelerate sales growth. Positive consumer responses to weight loss and ease of administration have already been confirmed in Ecuador, and exports of coglutide raw material (API) to Brazil will begin in earnest in March.
It also targets body management needs, including the non-obese cosmetic weight loss market, and is actively selling on the global e-commerce platform Amazon. Caregen plans to expand its market share by launching an additional sublingual formulation in late March or early April. Registration as a Novel Food is also underway with the European Union's EFSA, as well as in major South American countries such as Uruguay, Chile, Peru, Venezuela, Argentina, Paraguay, and Colombia.
“Registering in Mexico will be a turning point in the paradigm shift in the obesity and metabolic health sector,” said CEO Jeong Yong-ji. “We will expand our business throughout Central and South America to solidify our position as a leading global peptide wellness company.”
- See more related articles
You must be logged in to post a comment.